Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: A Groupe d'Etude des Lymphomes de l'Adulte trial

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 4, 2010, Pages 781-790

  Rolland, Delphine ^a   Ribrag, Vincent ^b   Haioun, Corinne ^c   Ghesquieres, Herve ^d   Jardin, Fabrice ^e   Bouabdallah, Reda ^f   Franchi, Patricia ^g   Briere, Josette ^g   De Kerviler, Eric ^g   Chassagne Clement, Catherine ^d   Raponi, Mitch ^h   Houlgatte, Remi ⁱ   Jais, Jean Philippe ^j   Thieblemont, Catherine ^g  

^a GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d CENTRE LÉON BÉRARD   (France)

^e CENTRE HENRI BECQUEREL   (France)

^f INSTITUT PAOLI CALMETTES   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h JOHNSON AND JOHNSON   (United States)

ⁱ UNIVERSITÉ DE NANTES   (France)

^j HÔPITAL NECKER ENFANTS MALADES   (France)

more..

Author keywords

Clinical trial; Mantle cell lymphoma; Molecular predictor; Tipifarnib

Indexed keywords

TIPIFARNIB; AKAP13 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; APTX PROTEIN, HUMAN; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; DNA BINDING PROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; NUCLEAR PROTEIN; ONCOPROTEIN; QUINOLONE DERIVATIVE; RASGRP1 PROTEIN, HUMAN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; DRUG DOSE REDUCTION; FEMALE; GENE EXPRESSION; HUMAN; MALE; MANTLE CELL LYMPHOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; DRUG ADMINISTRATION; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; ORAL DRUG ADMINISTRATION; PREDICTION AND FORECASTING; PROGNOSIS; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

A KINASE ANCHOR PROTEINS; ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; DNA-BINDING PROTEINS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; QUINOLONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 75749153294     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1185-4     Document Type: Article

References (52)

1. Jaffe E, Harris N, Stein H, Vardiman J (2008) World Health organization Classification of tumours. Tumours of haematopoietic and lymphoid tissues. IARC, Lyon
2. M Dreyling O Weigert W Hiddemann 2008 Current treatment standards and future strategies in mantle cell lymphoma Ann Oncol 19 Suppl 4 iv41 iv44 10.1093/annonc/mdn193 18519401
3. W Hiddemann M Unterhalt R Herrmann H Woltjen E Kreuser L Trumper M Reuss-Borst E Terhardt-Kasten M Busch A Neubauer U Kaiser R Hanrath H Middeke G Helm M Freund H Stein M Tiemann R Parwaresch 1998 Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group J Clin Oncol 16 1922 1930 1:STN:280:DyaK1c3ks1ehsQ%3D%3D 9586911
4. P Meusers M Engelhard H Bartels T Binder H Fulle K Gorge U Gunzer K Havemanne W Kayser E Konig, et al. 1989 Multicentre randomized trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis Leukemia 11 Suppl 2 S60 S64
5. D Decaudin J Bosq G Tertian G Nedellec A Bennaceur AM Venuat C Bayle P Carde B Bendahmane M Hayat JN Munck 1998 Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas J Clin Oncol 16 579 583 1:CAS:528:DyaK1cXhtFShtLs%3D 9469344
6. R Weide G Hess H Koppler J Heymanns J Thomalla A Aldaoud C Losem S Schmitz U Haak C Huber M Unterhalt W Hiddemann M Dreyling 2007 High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG) Leuk Lymphoma 48 1299 1306 10.1080/10428190701361828 1:CAS:528: DC%2BD2sXnsVyqsrc%3D 17613757 (Pubitemid 47082223)
7. RI Fisher BS Kahl B Djulbegovic MJ Robertson S de Vos E Epner A Krishnan JP Leonard S Lonial EA Stadtmauer OA O'Connor H Shi AL Boral A Goy 2006 Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma J Clin Oncol 24 4867 4874 10.1200/JCO.2006.07.9665 17001068 (Pubitemid 46655613)
8. TM Habermann IS Lossos G Justice JM Vose PH Wiernik K McBride K Wride A Ervin-Haynes K Takeshita D Pietronigro JB Zeldis JM Tuscano 2009 Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma Br J Haematol 145 344 349 10.1111/j.1365-2141. 2009.07626.x 1:CAS:528:DC%2BD1MXlslOhsrc%3D 19245430
9. I Khouri J Romaguera H Kantarjian J Palmer W Pugh M Korbling F Hagemeister B Samuels A Rodriguez S Giralt A Younes D Przepiorka D Claxton F Cabanillas R Champlin 1998 Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma J Clin Oncol 16 3803 3809 1:CAS:528:DyaK1MXosFyi 9850025
10. N Ketterer G Salles D Espinouse C Dumontet E Neidhardt-Berard I Moullet F Bouafia F Berger P Felman B Coiffier 1997 Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma Ann Oncol 8 701 704 10.1023/A:1008278605751 1:STN:280:DyaK2svkt1Sjug%3D%3D 9296227 (Pubitemid 27372172)
11. CH Geisler A Kolstad A Laurell NS Andersen LB Pedersen M Jerkeman M Eriksson M Nordstrom E Kimby AM Boesen O Kuittinen GF Lauritzsen H Nilsson-Ehle E Ralfkiaer M Akerman M Ehinger C Sundstrom R Langholm J Delabie ML Karjalainen-Lindsberg P Brown E Elonen 2008 Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group Blood 112 2687 2693 10.1182/blood-2008-03-147025 1:CAS:528:DC%2BD1cXht1SrtLfE 18625886
12. A Freedman D Neuberg J Gribben P Mauch R Soiffer D Fisher K Anderson N Andersen R Schlossman M Kroon J Ritz J Aster L Nadler 1998 High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission J Clin Oncol 16 13 18 1:CAS:528:DyaK1cXmtlersg%3D%3D 9440717
13. J Foran D Cunningham B Coiffier P Solal-Celigny F Reyes M Ghielmini P Johnson C Gisselbrecht M Bradburn J Matthews T Lister 2000 Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response Ann Oncol 11 Suppl 1 117 121 10.1023/A:1008309405678 10707792
14. Howard O, Gribben J, Neuberg D, Grossbard M, Poor C, janick M, Shipp M (1999) Rituxan/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma. In: The American Society of Hematology (Blood, ed) vol 94. The American Society of Hematology, New Orleans, p 631a
15. R Forstpointner M Unterhalt M Dreyling HP Bock R Repp H Wandt C Pott JF Seymour B Metzner A Hanel T Lehmann F Hartmann H Einsele W Hiddemann 2006 Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG) Blood 108 4003 4008 10.1182/blood-2006-04-016725 1:CAS:528:DC%2BD28XhtlWqsrrP 16946304 (Pubitemid 44920177)
16. S Bodrug B Warner M Bath G Lindeman A Harris J Adams 1994 Cyclin D1 ransgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene EMBO J 13 2124 2130 1:CAS:528:DyaK2cXksFCru70%3D 8187765
17. WK Hofmann S de Vos K Tsukasaki W Wachsman GS Pinkus JW Said HP Koeffler 2001 Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray Blood 98 787 794 10.1182/blood.V98.3.787 1:CAS:528:DC%2BD3MXlsFKru7w%3D 11468180
18. A Rosenwald G Wright A Wiestner WC Chan JM Connors E Campo RD Gascoyne TM Grogan HK Muller-Hermelink EB Smeland M Chiorazzi JM Giltnane EM Hurt H Zhao L Averett S Henrickson L Yang J Powell WH Wilson ES Jaffe R Simon RD Klausner E Montserrat F Bosch TC Greiner DD Weisenburger WG Sanger BJ Dave JC Lynch J Vose JO Armitage RI Fisher TP Miller M LeBlanc G Ott S Kvaloy H Holte J Delabie LM Staudt 2003 The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma Cancer Cell 3 185 197 10.1016/S1535-6108(03)00028-X 1:CAS:528: DC%2BD3sXhvFyrsrc%3D 12620412 (Pubitemid 37443390)
19. C Thieblemont V Nasser P Felman K Leroy S Gazzo B Loriod E Callet-Bauchu P Gaulard C Haioun A Traverse-Glehen S Granjeaud F Bertucci D Birnbaum F Magrangeas S Minvielle H Avet-Loiseau S Salles B Coiffier F Berger R Houlgatte 2004 Small lymphocytic lymphoma, marginal zone lymphoma, and mantle cell lymphoma exhibit distinct genomic profiles allowing molecular diagnosis Blood 103 2727 2737 10.1182/blood-2003-06-2160 1:CAS:528:DC%2BD2cXjtVaksLY%3D 14630827 (Pubitemid 38393031)
20. PJ Casey PA Solski CJ Der JE Buss 1989 p21ras is modified by a farnesyl isoprenoid Proc Natl Acad Sci USA 86 8323 8327 10.1073/pnas.86.21.8323 1:CAS:528:DyaK3cXltVOitA%3D%3D 2682646
21. EH Cheng DG Kirsch RJ Clem R Ravi MB Kastan A Bedi K Ueno JM Hardwick 1997 Conversion of Bcl-2 to a Bax-like death effector by caspases Blood 278 1966 1968 1:CAS:528:DyaK2sXotVClt70%3D
22. GJ Clark MS Kinch K Rogers-Graham SM Sebti AD Hamilton CJ Der 1997 The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation J Biol Chem 272 10608 10615 10.1074/jbc.272.16.10608 1:CAS:528:DyaK2sXisl2qsrY%3D 9099708 (Pubitemid 27181069)
23. Y Qiu X Liu W Zou P Yue S Lonial F Khuri S Sun 2007 The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells Cancer Res 67 4973 4980 10.1158/0008-5472.CAN-06-4044 1:CAS:528: DC%2BD2sXltl2gtr4%3D 17510428 (Pubitemid 46910206)
24. VA Fadok DR Voelker PA Campbell JJ Cohen DL Bratton PM Henzon 1992 Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages J Immunol 148 2207 2216 1:CAS:528:DyaK38XisFers7g%3D 1545126
25. M Sinensky K Fantle M Trujillo T McLain A Kupfer M Dalton 1994 The processing pathway of prelamin A J Cell Sci 107 61 67 1:CAS:528: DyaK2cXis1KmsrY%3D 8175923
26. HR Ashar L James K Gray D Carr S Black L Armstrong WR Bishop P Kirschmeier 2000 Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules J Biol Chem 275 30451 30457 10.1074/jbc.M003469200 1:CAS:528:DC%2BD3cXnt1agsbc%3D 10852915
27. A Adjee 2001 Blocking oncogenic Ras signaling for cancer therapy J Natl Cancer Inst 93 1062 1074 10.1093/jnci/93.14.1062
28. J Cortes M Albitar D Thomas F Giles R Kurzrock A Thibault W Rackoff C Koller S O'Brien G Garcia-Manero M Talpaz H Kantarjian 2003 Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies Blood 101 1692 1697 10.1182/blood-2002-07-1973 1:CAS:528:DC%2BD3sXhslCrsLc%3D 12411300 (Pubitemid 36237561)
29. JL Harousseau 2007 Farnesyltransferase inihibitors in hematologic malignancies Blood Rev 21 173 182 10.1016/j.blre.2006.12.001 1:CAS:528:DC%2BD2sXovFSjurw%3D 17293017 (Pubitemid 46887627)
30. R Kurzrock HM Kantarjian JE Cortes N Singhania DA Thomas EF Wilson JJ Wright EJ Freireich M Talpaz SM Sebti 2003 Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting Blood 102 4527 4534 10.1182/blood-2002-11-3359 1:CAS:528: DC%2BD3sXpslGrtrw%3D 12947010 (Pubitemid 37494120)
31. R Kurzrock M Albitar JE Cortes EH Estey SH Faderl G Garcia-Manero DA Thomas FJ Giles ME Ryback A Thibault P De Porre HM Kantarjian 2004 Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome J Clin Oncol 22 1287 1292 10.1200/JCO.2004.08.082 1:CAS:528:DC%2BD2cXpsVGktbs%3D 15051776 (Pubitemid 41079843)
32. Witzig T, Maurer M, Johnston P, Colgan J, Kaufmann S, Inwards D, Micallef I, Ansell S, Zent C, Allmer C, Weiner G, Wooldridge J, Link B, Habermann T (2008) Oral Tipifarnib (R115777) Has single agent anti-tumor activity in patients with relapsed aggressive non-hodgkin lymphoma (NHL): results of a phase II trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274). In: ASH (Blood, ed) vol 108, p Abstract 530
33. G Martinelli I Iacobucci S Paolini E Ottaviani 2008 Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib Clin Adv Hematol Oncol 6 303 310 18496498
34. P Epling-Burnette L Sokol X Chen F Bai J Zhou M Blaskovich J Zou J Painter T Edwards L Moscinski J Yoder J Djeu S Sebti TJ Loughran S Wei 2008 Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling Blood 112 4694 4698 10.1182/blood-2008-02-136382 1:CAS:528:DC%2BD1cXhsVCltbjM 18791165
35. D End 1999 Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway Investig New Drug 17 241 258 10.1023/A:1006380320290 1:CAS:528:DC%2BD3cXhtFart7Y%3D (Pubitemid 30037957)
36. D Rolland V Camara-Clayette A Barbarat G Salles B Coiffier V Ribrag C Thieblemont 2008 Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma Cancer Chemother Pharmacol 61 855 863 10.1007/s00280-007-0543-3 1:CAS:528:DC%2BD1cXitleqs78%3D 17639395 (Pubitemid 351305944)
37. N Yanamandra N Colaco N Parquet R Buzzeo D Boulware G Wright L Perez W Dalton D Beaupre 2006 Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia Clin Cancer Res 12 591 599 10.1158/1078-0432.CCR-05-1792 1:CAS:528:DC%2BD28XmtlKgsw%3D%3D 16428505 (Pubitemid 43166154)
38. M Raponi JL Harousseau JE Lancet B Löwenberg R Stone Y Zhang W Rackoff Y Wang D Atkins 2007 Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia Clin Cancer Res 13 2254 2260 10.1158/1078-0432.CCR-06-2609 1:CAS:528:DC%2BD2sXjs12rtb8%3D 17404110 (Pubitemid 46649895)
39. M Raponi JE Lancet H Fan L Dossey G Lee I Gojo EJ Feldman J Gotlib LE Morris PL Greenberg JJ Wright JL Harousseau B Löwenberg RM Stone P De Porre Y Wang JE Karp 2008 A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia Blood 111 2589 2596 10.1182/blood-2007-09-112730 1:CAS:528:DC%2BD1cXivFakt7g%3D 18160667
40. SR Johnston T Hickish P Ellis S Houston L Kelland M Dowsett J Salter B Michiels JJ Perez-Ruixo P Palmer A Howes 2003 Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer J Clin Oncol 21 2492 2499 10.1200/JCO.2003.10.064 1:CAS:528:DC%2BD2cXptlCktrY%3D 12829668 (Pubitemid 46606330)
41. Palmer A, Park Y, Hoffman K et al. (2003) A Phase 1 study in children to determine the maximum tolerable dose of farnesyltransferase inhibitor R115777 when administered chronically. J&JPRD Clinical study report R115777-INT-10
42. Richards H, De Porre P, Thibault A et al. (2003) A phase 2 trial to determine the antitumor activity of farnesyltransferase inhibitor R115777 in subjects with relapsed small cell lung cancer. J&JPRD Clinical study report - USA-8
43. B Cheson S Horning B Coiffier M Shipp R Fisher J Connors T Lister J Vose A Grillo-Lopez AA Hagenbeek F Cabanillas D Klippensten W Hiddemann R Castellino N Harris J Armitage W Carter R Hoppe G Canellos 1999 Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 1244 1:STN:280: DC%2BD3c%2FivF2itg%3D%3D 10561185
44. R Simon 1989 Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 10 10.1016/0197-2456(89)90015-9 1:STN:280: DyaL1M7ps1SjsQ%3D%3D 2702835 (Pubitemid 19099520)
45. L Fink W Seeger L Ermert J Hänze U Stahl F Grimminger W Kummer RM Bohle 1998 Real-time quantitative RT-PCR after laser-assisted cell picking Nat Med 4 1329 1333 10.1038/3327 1:CAS:528:DyaK1cXntlaru7s%3D 9809560 (Pubitemid 28512117)
46. L Chen S Monti P Juszczynski J Daley W Chen TE Witzig TM Habermann JL Kutok MA Shipp 2008 SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma Blood 111 2230 2237 10.1182/blood-2007-07-100115 1:CAS:528:DC%2BD1cXisVeit78%3D 18006696
47. MJ Robertson BS Kahl JM Vose S de Vos M Laughlin PJ Flynn K Rowland JC Cruz SL Goldberg L Musib C Darstein N Enas JL Kutok JC Aster D Neuberg KJ Savage A LaCasce D Thornton CA Slapak MA Shipp 2007 Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma J Clin Oncol 25 1741 1746 10.1200/JCO.2006.09.3146 1:CAS:528:DC%2BD2sXlvFyktbg%3D 17389337 (Pubitemid 46797955)
48. Friedberg J, Sharman J, Schaefer-Cutillo J, Johnston P, De Vos S, LaCasce A, Leonard J, Cripe L, Sinha R, SA G, Sweetenham J, Vose J, Lowe A, Levy R, Shipp M (2008) Fostamatinib Disodium (FosD), an oral inhibitor of Syk, is well-tolerated and has significant clinical activity in diffuse large B cell lymphoma (DLBCL) and chronic lymphocytic leukemia (SLL/CLL). In: ASH Annual Meeting San Francisco (Blood, ed) vol 112 p. Abstract 3
49. AD Seidman MN Fornier FJ Esteva L Tan S Kaptain A Bach KS Panageas C Arroyo V Valero V Currie T Gilewski M Theodoulou ME Moynahan M Moasser N Sklarin M Dickler G D'Andrea M Cristofanilli E Rivera GN Hortobagyi L Norton CA Hudis 2001 Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification J Clin Oncol 19 2587 2595 1:CAS:528:DC%2BD3MXkt1Omurk%3D 11352950
50. M Moroni S Veronese S Benvenuti G Marrapese A Sartore-Bianchi F Di Nicolantonio M Gambacorta S Siena A Bardelli 2005 Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study Lancet Oncol 6 279 286 10.1016/S1470-2045(05) 70102-9 1:CAS:528:DC%2BD2MXjs1Krsb8%3D 15863375 (Pubitemid 40590264)
51. JE Karp K Flatten EJ Feldman JM Greer DA Loegering RM Ricklis LE Morris E Ritchie BD Smith V Ironside T Talbott G Roboz SB Le XW Meng PA Schneider NT Dai AA Adjei SD Gore MJ Levis JJ Wright E Garrett-Mayer SH Kaufmann 2009 Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase I trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide Blood 113 4841 4852 10.1182/blood-2008-08-172726 1:CAS:528:DC%2BD1MXmslalsb0%3D 19109557
52. J Cortes A Quintás-Cardama G Garcia-Manero S O'Brien D Jones S Faderl T Ebarb F Giles D Thomas H Kantarjian 2007 Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure Cancer 110 2000 2006 10.1002/cncr.23006 1:CAS:528:DC%2BD2sXhtlertbrK 17849425 (Pubitemid 350036859)